M. Lebwohl

Immunology · 2001–2019

A researcher in the Science corpus: 10 papers; trusts 4 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Immunology — 125 citations into it
• Hematology — 7 citations into it
• Genetics — 6 citations into it

Whom M. Lebwohl trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. S. Brand
2. Brigitta Stockinger

Papers from M. Lebwohl's perspective

Ordered by how strongly the researchers M. Lebwohl trusts endorse each paper. Same corpus, a different order for every researcher.

1. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. (New England Journal of Medicine)
2. IL‐22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis (European Journal of Immunology)
3. Etanercept as monotherapy in patients with psoriasis. (New England Journal of Medicine)
4. Development, cytokine profile and function of human interleukin 17–producing helper T cells (Nature Immunology)
5. Increased Expression of Interleukin 23 p19 and p40 in Lesional Skin of Patients with Psoriasis Vulgaris (Journal of Experimental Medicine)
6. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses (Journal of Experimental Medicine)
7. Sequence and haplotype analysis supports HLA-C as the psoriasis susceptibility 1 gene. (American Journal of Human Genetics)
8. Risk of myocardial infarction in patients with psoriasis. (Journal of the American Medical Association (JAMA))
9. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. (Journal of Clinical Investigation)
10. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. (Archives of Dermatology)

Their papers

• Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. (2019) — 854 citations
• Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. (2015) — 761 citations
• Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. (2015) — 816 citations
• Secukinumab in plaque psoriasis--results of two phase 3 trials. (2014) — 1,859 citations
• Review of ustekinumab, an interleukin-12 and interleukin-23 inhibitor used for the treatment of plaque psoriasis (2010) — 89 citations
• Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). (2008) — 1,100 citations
• Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. (2008) — 1,339 citations
• Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. (2008) — 798 citations
• A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. (2007) — 812 citations
• The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. (2001) — 1,049 citations